Colon cancer prevention: Intervening in a multistage process

Proceedings of the Society for Experimental Biology and Medicine

Volumn 216, Issue 2, 1997, Pages 266-274

  Bertagnolli, Monica M ^a,b   McDougall, Carl J ^a,b   Newmark, Harold L ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b STRANG CANCER PREVENTION CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLYL SULFIDE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CALCIUM; FLAVANOID; FOLIC ACID; INDOLE DERIVATIVE; INOSITOL; ISOTHIOCYANIC ACID; LINOLEIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTIC ACID; PROSTAGLANDIN SYNTHASE INHIBITOR; SELENIUM; SULINDAC; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; COLON CANCER; DIET; DIETARY FIBER; HIGH RISK POPULATION; HUMAN; REVIEW; SCREENING;

EID: 0030798241     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-216-44177     Document Type: Review

References (99)

1. Vogelstein B, Fearon ER, Hamilton S, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532, 1988.
2. Burt R, Bishop DT, Cannon LA, Dowdle MA, Lee RG, Skolnick MH. Dominant inheritance of adenomatous colonic polyps and colorectal cancer. N Engl J Med 321:1540-1544, 1985.
3. Solomon E, Voss R, Hall V, Bodmer WF, Jass JR, Jeffreys AJ, Lucibello FC, Patel I, Rider SH. Chromosome 5 allele loss in human colorectal carcinomas. Nature 328:616-619, 1987.
4. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990.
5. Shpitz B, Hay K, Medline A, Bruce WR, Bull SB, Gallinger S, Stern H. Natural history of aberrant crypt foci. Dis Colon Rectum 39:763-767, 1996.
6. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54:5523-5526, 1994.
7. Fearon ER, Vogelstein B. A genetic model for colorectal carcinogenesis. Cell 61:759-767, 1990.
8. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries with special reference to dietary practices. Int J Cancer 15:617-631, 1975.
9. Sherlock P, Lipkin M, Winawer SJ. Predisposing factors in carcinoma of the colon. Adv Intern Med 20:121-150, 1975.
10. Reddy BS, Simi B, Engle A. Biochemical epidemiology of colon cancer: Effect of types of dietary fiber on colonic diacylglycerols in women. Gastroenterology 106:883-889, 1994.
11. Alberts DS, Einspahr J, Rees-McGee S. Effects of dietary wheat bran on rectal epithelial cell proliferation in patients with resection for colorectal cancers. J Natl Cancer Inst 84:1887-1896, 1992.
12. Newmark HL, Wargovich MJ, Bruce WE. Colon cancer and dietary fat, phosphate, and calcium: A hypothesis. J Natl Cancer Inst 72:1323-1325, 1984.
13. Morotomi M, Guillem J, LoGerfo P, Weinstein IB. Production of diacylglycerol, an activator of protein kinase C, by human intestinal microflora. Cancer Res 50:3595-3599, 1990.
14. Haenszel W, Berg JW, Segi M, Kurihara M, Locke FB. Large bowel cancer in Hawaiian Japanese. J Natl Cancer Inst 51:1765-1799, 1973.
15. Van Tassell RL, Kingston DGI, Wilkins TD. Metabolism of dietary genotoxins by the human colonic microflora: The fecapentaenes and heterocyclic amines. Mutat Res 238:209-221, 1990.
16. Newmark HL. A hypothesis for dietary components as blocking agents of chemical carcinogenesis: Plant phenolics and pyrrole pigments. Nut Cancer 6:58-70, 1984.
17. Richter F, Newmark HL, Richter A, Leung D, Lipkin M. Inhibition of Western-diet induced proliferation and hyperplasia in mouse colon by two sources of calcium. Carcinogenesis 16:2685-2689, 1995.
18. Buset M, Lipkin M, Winawer S, Swaroop S, Friedman E. Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium. Cancer Res 46:5426-5430, 1986.
19. Appleton GVN, Owen RW, Wheeler EE, Challacombe DN, Williamcon RCN. Effect of dietary calcium on the colonic luminal environment. Gut 32:1374-1377, 1991.
20. 3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53:3712-3718, 1993.
21. Burkitt D. Related disease - Related cause? Lancet 2:1229-1231, 1969.
22. Giovannucci E, Stamffer MJ, Colditz G, Rimm EB, Willett W. Relationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst 84:91-98, 1992.
23. Howe GR, Benito E, Castello R, Cornee J, Esteve J, Gallagher RP, Iscovich JM, Deng-ao J, Kaaks R, Kune GA, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: Evidence from the analysis of 13 case-control studies. J Natl Cancer Inst 84:91-98, 1992.
24. Willett WC, Stamffer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 326:1664-1672, 1990.
25. Potter JD. Reconciling the epidemiology, physiology, and molecular biology of colon cancer. JAMA 268:1573-1577, 1992.
26. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 54:2390-2397, 1994.
27. Newmark HL, Lipkin M, Maheshwari N. Colonic hyperproliferation induced in rats by nutritional-stress diets containing four components of a human Western-style diet. Am J Clin Nutr 54:209-214, 1991.
28. Hill MJ, Aries VC. Faecal steroid composition and its relationship to cancer of the large bowel. J Pathol 104:129-139, 1971.
29. Chomchai C, Bhadrachari N, Nigro ND. The effect of bile on the induction of experimental intestinal tumors in rats. Dis Colon Rectum 17:310-312, 1974.
30. Reddy BS, Wynder EL. Large bowel carcinogenesis: Fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst 50:1437-1442, 1973.
31. Goldbohm RA, van der Brandt PA, van't Veer P, Brants HA, Dorant E, Sturmans F, Hermus RJ. A prospective cohort study on the relation between meat consumption and the risk of colon cancer. Cancer Res 54:718-723, 1994.
32. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: A review of the epidemiology. Epidemiol Rev 15:499-545, 1993.
33. Bostick RM, Potter JW, Sellers TA, McKenzie DR, Kushi LH, Folsour AR. Relation of calcium, vitamin D, dairy food intake to increase of colon cancer among older women. Am J Epidemiol 137:1302-1317, 1993.
34. Wargovich MJ, Isbell G, Shabot M, Winn R, Lanza F, Hochman L, Larson E, Lynch P, Roubein L, Levin B. Calcium supplementation decreases rectal epithelial cell proliferation in subjects with sporadic adenomas. Gastroenterology 103:92-97, 1992.
35. Newmark HL, Lipkin M. Calcium, vitamin D and colon cancer. Cancer Res 52:2067-2070, 1992.
36. Kampman E, Giovannucci E, van't Veer P, Rimm E, Stampfer MJ, Colditz FA, Kok FJ, Willett WC. Calcium, vitamin D, diary foods and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol 139:16-29, 1994.
37. Robinson MF, Godfrey PJ, Thomson CD, Rea HM, van Rij AM. Blood selenium and glutathione peroxidase activity in blood of New Zealand residents. Am J Clin Nutr 32:1477-1485, 1979.
38. Jacobs MM, Matney TS, Griffin AC. Inhibitory effects of selenium on the mutagenicity of 2-acetylaminofluorine (AAF) and AAF derivatives. Cancer Lett 2:319-322, 1988.
39. Shamberger RJ. Relationship of selenium to cancer. I. Inhibitory effect of selenium on carcinogenesis. J Natl Cancer Inst 44:931-936, 1970.
40. Broghamer WL Jr., McConnell KP, Blotcky AJ. Relationship between serum selenium levels and patients with carcinoma. Cancer 37:1384-1388, 1976.
41. Willett WC, Polk BF, Morris JJS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG. Prediagnostic serum selenium and risk of cancer. Lancet 2:130-134, 1983.
42. Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr., Beck GJ, Bond JH, Colacchio TA, Collier JA, Frankl HD, Haile RW, et al. Clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 33:141-147, 1994.
43. Giovannucci E, Rimm EB, Ashierio A, Stampfer MJ, Colditz CA, Willett WC. Alcohol, low-methionine, low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 87:265-273, 1995.
44. Steinmetz K, Potter J. Vegetables, fruit, and cancer, II: Mechanisms. Cancer Causes Control 58:195-198, 1991.
45. Wattenberg LW. Inhibition of chemical carcinogenesis. J Natl Cancer Inst 60:11-18, 1987.
46. Garfinkel L, Stellman SD. Mortality by relative weight and exercise. Cancer 62:1844-1850, 1988.
47. Ballard-Barbash R, Schatzkin A, Albanes D, Schiffman MH, Kreger BE, Kannel WB, Anderson KM, Helsel WE. Physical activity and risk of large bowel cancer in the Framington study. Cancer Res 50:3610-3613, 1990.
48. Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN, Berry TD. Energy balance and colon cancer - Beyond physical activity. Cancer Res 57:75-80, 1997.
49. Kearney J, Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Bleday R, Willett WC. Diet, alcohol and smoking and the occurrence of hyperplastic polyps of the colon and rectum (United States). Cancer Causes Control 6:45-56, 1995.
50. Klatsky AL, Armstrong MA, Friedman GD, Hiatt RA. The relations of alcoholic beverage use to colon and rectal cancer. Am J Epidemiol 128:1007-1015, 1988.
51. Thun MJ, Namboodiri BS, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991.
52. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995.
53. Min mouse model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res 56:710-714, 1996.
54. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 47:5340-5346, 1987.
55. Pollard M, Luckert PH. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 25:117-121, 1984.
56. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 156:341-347, 1988.
57. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55:1464-1472, 1995.
58. Reddy BS, Rao CV, Rivenson A, Kelloff GJ. Inhibitory effect of aspirin on azoyxmethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (Lond) 14:1493-1497, 1993.
59. Reddy BS, Tokumo K, Kulkami N, Aligia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13:1019-1023, 1992.
60. Metzger U, Meier J, Uhlschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 27:366-369, 1984.
61. Narisawa T, Staoh M, Sano M, Takahashi T. Inhibition of initiation and promotion on N-methylnitrosourea-induced colon carcinogenesis in rats by nonsteroidal anti-inflammatory agent indomethacin. Carcinogenesis (Lond) 14:1493-1497, 1993.
62. Klein WA, Miller HH, Anderson M, DeCosse JJ. The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer 60:2863-2868, 1987.
63. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 26:85-101, 1997.
64. Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology 93:109-1013, 1987.
65. Gilbertsen VA. Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer. Cancer 34:936-939, 1974.
66. Atkin WS, Morson BC, Cuzik J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326:658-662, 1992.
67. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326:653-657, 1992.
68. Newcomb PA, Norfleet RG, Storer BE, Suranwicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572-1575, 1992.
69. DiSario JA, Foutch PG, Mai HD, Pardy K, Manne RK. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. Am J Gastroenterol 86:946-951, 1991.
70. Lieberman D, Smith F. Screening asymptomatic subjects for colon malignancy with colonoscopy. Am J Gastroenterol 86:946-951, 1991.
71. Gillespie PE, Chambers TJ, Chan KW, Doronzo F, Morson BC, Williams CB. Colonic adenomas - A colonoscopy study. Gut 20:240-245, 1979.
72. Toribara NW, Sleisinger MH. Screening for colorectal cancer. N Engl J Med 332:861-867, 1995.
73. Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 86:946-951, 1991.
74. Morson BC. The evolution of colorectal carcinoma. Clin Radiol 35:425-430, 1984.
75. Brahm F, Ekelund GR, Norden JG, Wenkert A. Metachronous colorectal polyps: Comparison of development of colorectal polyps and carcinomas in persons with and without histories of polyps. Dis Colon Rectum 29:383-387, 1986.
76. Mandel JS, Bond J, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328:1365-1371, 1993.
77. Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: Sensitivity, specificity, and predictive value. Ann Int Med 112:328-333, 1990.
78. Winawer SJ, Zauber AG, May NH, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329:1977-1981, 1993.
79. Winawer SJ, Zauber A, O'Brien MJ, Ho MN, Gottlieb LS, Sternberg SS, Waye JD, Bond JH, Schapiro M, Stewart ET, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 328:901-906, 1993.
80. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: Modulating effect of types and amount of dietary rat on ras-p21 function during promotion and progression stages of colon cancer. Cancer Res 57:253-258, 1997.
81. Zhang Y, Talalay P. Anticarcinogenic activities of organic isothiocyanates: Chemistry and mechanisms. Cancer Res 54:19765-19815, 1994.
82. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 92:5258-5265, 1995.
83. Salamoto K, Venkatraman G, Shamsuddin AM. Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 14:1815-1819, 1993.
84. Rao CV, Desai D, Simi B, Kulkarni N, Amin S, Reddy B. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res 53:4182-4188, 1993.
85. Anti M, Marra G, Armelao F, Bartoli GM, Ficarelli R, Percesepe A, De Vitis I, Maria G, Sofo L, Rapaccini GL, et al. Effect of ω3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 103:883-891, 1992.
86. Belury MA. Conjugated dienoic linoleate: A polyunsaturated fatty acid with unique chemopreventive properties. Nutr Rev 53:83-89, 1995.
87. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally-occurring plant phenolic compound. Cancer Res 55:259-266, 1995.
88. Deschner EE, Ruperto J, Wong G, Newmark HL. Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 12:1193-1196, 1991.
89. Aldercreutz M. Western diet and western diseases: Some humoral and biochemical mechanisms and associations. Scand J Lab Invest 50(Suppl 201):3-23, 1990.
90. Serraino M, Thompson LU. The effect of flaxseed supplementation on the initiation and promotional stages of mammary carcinogenesis. Nutr Cancer 17:153-159, 1992.
91. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 24:83-87, 1983.
92. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 157:175-179, 1989.
93. Labayle D, Fischer D, Vielh P, Drouhin F, Patiente A, Bories C, Dhamel O, Trosset M, Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639, 1991.
94. Δ716 knockout mice by inhibition of cyclooxygenase 2. Cell 87:803-809, 1996.
95. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566-4569, 1996.
96. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G. Randomized phase I chemoprevention dose-seeking study of α-difluoromethylornithine. J Natl Cancer Inst 85:732-737, 1993.
97. Kennedy AR, Beazer-Barclay Y, Kinzler KW, Newberne PM. Suppression of carcinogenesis in the intestines of Min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 56:679-682, 1996.
98. Rao CV, Rivenson A, Katiwalla M, Kelloff GJ, Reddy BS. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 53:2502-2506, 1993.
99. Kensler TW, Helzlsouer KJ. Oltipraz: Clinical opportunities for cancer chemoprevention. J Cell Biochem Suppl 22:101-107, 1995.